분류 전체보기 썸네일형 리스트형 전신성 홍반성 루푸스 환자에서 발작, Seizures, neurologic manifestations of systemic lupus erythematosus 발작은 전신성 홍반성 루푸스 환자의 약 10 ~ 20 %에서 발생합니다. 전신 발작(generalized seizures)과 부분 발작(partial seizures)이 모두 일어날 수 있습니다. 후자는 complex(complex partial seizures) 또는 simple(focal epilepsy)일 수 있습니다. 발작은 루푸스의 첫 징후일 수 있으며, 병의 진행 과정에서 발생할 수 있습니다. 어느 사례 시리즈에서 새롭게 발생한 발작의 약 절반이 진단 후 첫 해 동안 발생했습니다. 발작의 원인은 다양하며 acute inflammatory episode 또는 old CNS damage with scarring을 반영할 수 있습니다. 또한 aPL, 대사 장애(예 : 요독증), 고혈압, 감염, 종양.. 2018 AACE/ACE comprehensive type 2 diabetes management algorithm 2018 AACE lipid targets for patients with T2D Major independent risk factors are high LDL-C, polycystic ovary syndrome, cigarette smoking, hypertension (blood pressure ≥140/90 mm Hg or on hypertensive medication), low high-density lipoprotein cholesterol ( 고령 당뇨병 환자에서 당화혈색소 목표, Treatment goals of older adults with diabetes 병합 치료(스타틴/피브레이트, 스타틴/니아신), Combination therapy(statin/fibrate or statin/niacin) Statin and Fibrate Combination therapy (statin and fibrate) is associated with an increased risk for abnormal transaminase levels, myositis, and rhabdomyolysis. The risk of rhabdomyolysis is more common with higher doses of statins and renal insufficiency and appears to be higher when statins are combined with gemfibrozil (compared with fenofibrate). In the ACCORD study, in patients with type 2 .. Recommendations for statin and combination treatment in adults with diabetes, 2018 ADA ASCVD risk factors include LDL cholesterol ≥ 100 mg/dL (2.6 mmol/L), high blood pressure, smoking, chronic kidney disease, albuminuria, and family history of premature ASCVDRecommendations ● For patients of all ages with diabetes and atherosclerotic cardiovascular disease, high-intensity statin therapy should be added to lifestyle therapy. A ● For patients with diabetes aged < 40 years with addi.. 당뇨병 환자에서 고혈압 치료 권고 사항, 2018 ADA 참고문헌 Antihyperglycemic therapy, type 2 DM, 2018 ADA When A1C is ≥ 9% (75 mmol/mol), consider initiating dual combination therapy (Fig. 8.1) to more expeditiously achieve the target A1C level. If the A1C target is notachievedafterapproximately 3months and patient does not have atherosclerotic cardiovascular disease (ASCVD), consider a combination of metformin and any one of the preferred six treatment options: sulfonylurea, thiazolidinedione, DPP-.. 이전 1 ··· 358 359 360 361 362 363 364 ··· 406 다음
